Good morning, and welcome to the CorMedix Fourth Quarter and Full Year 2025 Earnings and Corporate Update Conference Call. Leading the call tod ...
NEUTROGUARD study: Phase III clinical study of DEFENCATH for prevention of CLABSI in adults on TPN via central venous catheter.
Cormedix Inc (CRMD) reports robust financial performance with significant revenue from DefenCAF and successful integration of Mota Therapeutics.
Geelong will take an injury-battered forward line north to face Gold Coast with captain Patrick Dangerfield and Coleman medallist Jeremy Cameron both ruled out of the opening round clash.
A city hall committee in Winnipeg has voted against the installation of temporary bike lanes on Wellington Crescent this year. Instead, they have chosen to pursue permanent, protected lanes, with ...
The company is affirming 2026 DefenCath guidance of $150 million to $170 million, 2027 DefenCath guidance of $100 million to $125 million, and full year 2026 financial guidance of revenue of $300 ...
See an updated list of injuries, with active and inactive players for the Ottawa Senators vs. Calgary Flames NHL March 5 game ...
See an updated list of injuries, with active and inactive players for the Columbus Blue Jackets vs. Florida Panthers NHL March 5 game.
Sight Scotland Veterans supports veterans living with vision impairment in West Lothian and across Scotland - reducing isolation, rebuilding confidence, and strengthening mental well‑being ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results